-alkylguanine DNA alkyltransferase (AGT) is a key mechanism in the prevention against MNU induced malignant transformation by removal of O 6 methyl guanine (O 6 mG) adducts. We asked whether heterozygous p53 de®cient mice (p53+/7) would be more susceptible to MNU induced lymphomas than wild type mice, and whether O 6 mG adducts were responsible for this susceptibility. To determine whether MGMT overexpression would be protective, p53+/7 mice were bred to human MGMT transgenic mice (MGMT+) and treated with 50 mg/kg MNU. MNU increased the incidence of thymic lymphomas in non-transgenic p53+/7 mice from 23% (n=13) to 68% (n=22) and decreased the mean latency from 433 to 106 days (P=0.01 compared to untreated mice). Wild type mice had an incidence of 30% (n=38) and a mean latency of 135 days after MNU. Overexpression of MGMT in the thymus of p53+/7 mice signi®cantly reduced the lymphoma incidence from 68 to 28% (n=17) and increased the latency from 106 to 167 days (P=0.003). Similarly, the lymphoma incidence in MGMT+/wild type mice decreased from 30 to 8% (n=12) and the latency increased to 297 days (P=0.2). Loss of the wild type allele was found in only 2/17 lymphomas occurring in p53+/7 mice and there were no signi®cant point mutations in exons 5 ± 8 of p53. Furthermore, there was no loss of p53 function in these mice. These data demonstrate that unrepaired O 6 mG lesions act cooperatively with the reduced p53 dose and lead to lymphomagenesis in p53+/7 mice, but AGT overexpression and rapid removal of O 6 mG adducts is protective. Oncogene (2001) 20, 5258 ± 5263.
Introduction
-alkylguanine DNA alkyltransferase (AGT) is critical in the prevention of tumorigenesis. AGT, encoded by MGMT, repairs mutagenic O 6 methyl guanine (O 6 mG) adducts by transferring the methyl group to a cysteine residue within its active site in an irreversible and stoichiometric reaction (Pegg, 1990) . Transgenic mice which overexpress human MGMT are markedly protected from induction of thymic lymphomas by the methylating agent MNU (Dumenco et al., 1993) . Furthermore, targeted disruption of MGMT renders mice sensitive to the carcinogenic eect of alklyating agents (Tsuzuki, et al., 1996; Glassner et al., 1999) . Thus, AGT by removal of O 6 mG adducts is an important mechanism in the protection against MNU induced carcinogenesis.
Overexpression of MGMT has also been shown to protect genetically predisposed mice from spontaneous and MNU induced thymic lymphomas. We showed that MGMT blocked the carcinogenic eect of MNU in mice de®cient in the DNA repair gene PMS2 (Qin et al., 1999a) and in mice transgenic for LMO1 (Allay et al., 1997) , a gene which is associated with T-cell lymphomas in humans and transgenic mice (McGuire et al., 1992; Neale et al., 1995) through transcriptional activation of genes regulating T-cell development and proliferation.
p53 inactivation is the most common molecular event detected in human tumors. The somatic mutation in human tumors is usually a point mutation in one allele accompanied by a loss of the second allele (Hollstein et al., 1991; Nigro et al., 1989) . Alternatively, and less common, is a rearrangement of both p53 alleles or maintenance of one wild type and one mutant allele (Levine et al., 1991; Nigro et al., 1989; Masuda et al., 1987) . Mice homozygous for a null allele of p53 are highly susceptible to spontaneous tumors, particularly thymic lymphomas (Harvey et al., 1993) . Mice with a single p53 null allele (heterozygotes) are also predisposed to spontaneous tumors with a delayed onset compared to homozygotes, but show increased susceptibility to chemical carcinogens such as DMN and MNU (Harvey et al., 1993; Ohgaki et al., 2000) .
In the current studies we queried whether p53 heterozygous mice would be more susceptible to MNU induced lymphomas than wild type mice and whether O 6 mG adducts are responsible for this susceptibility. We hypothesized that O 6 mG lesions would potentiate lymphomagenesis due to the p53 gene dosing eect and that we could prove this by overexpression of MGMT in the thymus which should protect the p53 heterozygous mouse. This would provide direct evidence that it is the O 6 mG adduct which is carcinogenic in these mice. Alternatively, if little or no protective eect of MGMT were observed in p53 heterozygous mice after MNU, it would suggest that other DNA adducts formed by MNU might be carcinogenic in the absence of p53. Indeed, the majority of adducts formed by MNU-N 7 methylguanine and N 3 methyladenine are known to be both mutagenic and cytotoxic, but in the normal mouse, contribute little to carcinogenesis. To demonstrate the role of O 6 mG repair in carcinogenesis in heterozygous p53 de®cient mice, these mice were crossed with MGMT transgenic mice and treated with a single dose of 50 mg/kg MNU. Our results demonstrate that lymphomagenesis was potentiated by MNU in p53 heterozygotes and overexpression of MGMT decreased the incidence and increased the latency of thymic lymphoma induction in mice with both heterozygous and wild type p53 alleles. The potentiation did not commonly result in the loss of the remaining wild type allele. These results indicate that despite the fact that p53 mutations are not a primary target of MNU lymphomagenesis, thymic overexpression of MGMT and AGT removal of O 6 mG adducts can protect mice with only a single copy of p53 from MNU induced lymphomagenesis.
Results

MNU induced Iymphomas in p53 heterozygous mice
F1 MGMT (+) transgenic mice were bred to p53 heterozygotes resulting in the progeny (genotype designated as MGMT/p53): non-transgenic/wild type p53; non-transgenic/hetero p53, MGMT+/wt p53 and MGMT+/hetero p53. To determine whether MNU potentiates thymic lymphomas in mice de®cient in one p53 allele, each group of mice was treated with 50 mg/ kg MNU at 6 weeks of age or left untreated. Mice were sacri®ced when they exhibited signs of thymic lymphoma (shortness of breath) and were found to have an enlarged thymus which, in most cases, encased the heart. Histological analysis revealed cells consistent with T-cell lymphoblastic lymphoma. p53 heterozygotes developed spontaneous thymic lymphomas at a 23% incidence (n=13) with a mean latency of 433 days (Figure 1 ) while wild type mice developed no lymphomas (data not shown). Other tumor types, including rhabdomyosarcoma, ovarian and testicular, with a short latency developed no untreated p53 heterozygotes and were censored as indicated in Figure  1 by open circles. As a control, p53 mice homozygous for a null allele were also observed. As expected based on previous reports, p537/7 had a spontaneous incidence of lymphomas of 83% (n=6). MNU treatment signi®cantly potentiated lymphomagenesis in both p53 heterozygotes and wild type mice. Thymic lymphoma incidence in p53 heterozygotes increased to 68% (n=22) and the mean latency decreased to 106 days (P=0.01 compared to untreated p53+/7 mice) ( Figure 2a ). MNU treatment of wild type mice resulted in an incidence of 30% (n=38) and a mean latency of 135 days (P=0.02 compared to untreated wild type mice) (Figure 2b ).
MNU induced lymphomas in mice overexpressing MGMT
To determine the ability of MGMT overexpression and rapid O 6 mG repair to protect genetically predisposed mice against spontaneous and MNU induced lymphomas, MGMT+/wt p53 and MGMT+/hetero p53 mice were treated with 50 mg/kg MNU at 6 weeks of age or left untreated. Overexpression of MGMT in wild type mice reduced the incidence from 30% in non-transgenic mice to 8% (n=12) and increased the latency from 135 to 297 days (P=0.2) (Figure 2c ). Likewise, overexpression of MGMT in p53 heterozygous mice reduced the lymphoma incidence from 68 to 28% (n=17) and increased the mean latency from 106 to 167 days (P=0.003), similar to that observed in mice expressing wild type p53 (Figure 2d ). Furthermore, the presence of MGMT reduced the spontaneous incidence of lymphoma in p53 heterozygotes from 23 to 0% (n=13) P=0.1 (Figure 1 ). These data indicate that an MNU induced O 6 mG adduct is the oending lesion potentiating lymphomagenesis in both wild type and p53 heterozygous mice.
Phenotype of thymic lymphomas
Phenotype of the lymphomas was determined by¯ow cytometry of surface antigens and de®ned by 435% cells staining positive. All lymphomas were Thy 1+, indicating T-cell origin, and only 50% were positive for surface TCR. Of those expressing TCR, 35% were CD4+/CD8+ and 15% CD4+/CD87. Surface marker characteristics were independent of p53 or MGMT status. Thus lymphomagenesis appears to be à ®nal common pathway' in the malignant transformation of murine T-cells.
Analysis for K-ras mutations and loss of p53 heterozygosity
G to A point mutations in codon 12 of K-ras, which are known to activate K-ras pathway signaling and which have been shown to occur in MNU induced Figure 2 MNU induced lymphoma incidence in p53 heterozygotes and wild type mice in the presence and absence of the human MGMT transgene. Mice were derived by crossbreeding MGMT transgenic and p53 heterozygous mice (resulting genotypes designated: wild type, p53 hetero, MGMT/wild type and MGMT/p53 hetero). Mice were treated with MNU at 6 weeks of age and monitored daily for development of thymic lymphomas. After sacri®ce, mice were autopsied and tissues were examined by H&E staining. Filled symbols indicate mice exhibiting thymic lymphoma; open symbols indicate other cause of death or sacri®ce at 1 year thymic lymphomas, were detected using PCR ± RFLP analysis. Of 23 MNU induced lymphomas tested, only one wild type mouse and no p53 heterozygous mice demonstrated a G to A point mutation in K-ras. To determine the fate of the wild type p53 allele in lymphomas that developed in MNU treated p53 heterozygotes, PCR was performed using primers speci®c for wild type and mutant p53. Both the mutant and wild type allele were ampli®ed in 15/17 lymphomas tested (Figure 3 ), indicating that in the majority of the lymphomas there were no gross rearrangements or deletions leading to disruption of the wild type allele. The possibility of a point mutation was examined by PCR ampli®cation of the p53 gene from genomic DNA followed by sequencing of exons 5 through 8 (n=9 mice). This is a highly conserved DNA binding domain of the protein and the region where most human tumor p53 mutations have been identi®ed. With the exception of one T to A mutation in codon 15 of exon 7 resulting in an asparagine to lysine mutation, no other point mutations were detected. Thus, it appears that acquired mutations in p53 after MNU were not commonly observed.
p53 functional analysis
Since we observed lymphomas in p53 heterozygotes but no mutations in the wild type p53 allele, we asked whether p53 was functional by analysis of p21 expression. P53 was induced in two mice exhibiting signs of lymphoma by exposure to 500 cGy 60 Co. Subsequent Western blot analysis for p21 expression revealed protein levels equal to the wild type control (Figure 4) , suggesting that p53 functioned normally in these mice.
Discussion
In this study we used the well characterized mouse model of MNU induced lymphomagenesis to determine whether O 6 mG adducts would lead to increased tumor susceptibility of mice lacking one allele of p53. It is well known from previous studies that the lack of p53 functions as an promoting event in tumorigenesis since homozygous null mice develop tumors at an incidence of 100% by 10 months and p53 heterozygotes exhibit an incidence of 50% by 18 months, a rate signi®cantly greater than observed in mice with normal p53 (Harvey et al., 1993) . Due to the low background of spontaneous tumors in p53 heterozygotes, we chose these mice for carcinogenesis experiments.
Here we demonstrate that lymphoma development in mice de®cient in one allele of p53 have an increased incidence of MNU induced thymic lymphomas compared to MNU treated wild type mice and also have an increased incidence compared to untreated p53 heterozygotes. Based on previous studies in wild type mice showing that O 6 mG adduct is the carcinogenic lesion after MNU treatment (Dumenco et al., 1993) , we investigated whether overexpression of human MGMT would protect p53 de®cient mice. We have shown that MGMT transgenic mice eciently remove O 6 mG adducts and only 3% remain 18 h after 80 mg/kg MNU compared to 84% in non-transgenics (Liu, et al., 1994) . In fact, p53 heterozygotes cross-bred to hMGMT transgenic mice had a signi®cant decrease in MNU induced lymphomas, with a decline in incidence from 68 to 28% and an increased latency. hMGMT overexpression also protected control wild type mice from MNU induced lymphomas, and p53 heterozygotes from spontaneous lymphomas, strongly indicating that the O 6 mG adduct, and not other DNA adducts, potentiated lymphoma development in these mice. MNU does induce a number of other methylation sites including N 7 mG and N 3 mA, and we have shown high residual mutation frequency in the thymus of mice transgenic for MGMT given MNU, even though the lymphoma rate is very low (Allay et al., 1999) . This suggests that N 7 mG and N 3 mA, repaired by the base excision repair pathway, are mutagenic but not carcinogenic, even in the setting of reduced p53 expression. An association between p53, the base excision repair pathway and modulation of apoptosis has recently been demonstrated (Oer et al., 2001) , and emphasizes the signi®cance of this observation that lymphomagenesis after MNU, in the setting of reduced p53, is due to unrepaired O 6 mG adducts. Based on the late onset of spontaneous tumors in p53 heterozygotic mice (12 ± 18 months) (Harvey et al., 1993) as well as the long latency in tumorigenesis observed in Li Fraumeni patients carrying a germline mutation in one p53 allele (Li et al., 1988) , it appears that the reduced gene dose' of p53 does not result in an immediate Figure 3 Fate of the wild type allele in p53 heterozygote lymphomas. DNA from lymphomas that developed in MNU treated p53 heterozygotes was PCR ampli®ed using primers speci®c for wild type p53 and mutant p53. Representative samples demonstrate loss of the wild type allele in lane 4 Figure 4 Western blot demonstrating p21 expression in p53 heterozygote lymphomas. Normal mice and p53 heterozygotes exhibiting symptoms of thymic lymphoma were irradiated with 500cGy and sacri®ced 4 h later. Protein was isolated from lymphoma tissue and subjected to Western blot using an antibody to p21 selective advantage but requires another carcinogenic event such as a complementing mutation at another loci. This may be a second p53 mutation in the remaining allele or perhaps epigenetic change in gene expression due to altered methylation or spontaneous induced activation of a cooperative oncogene such as K-ras or loss of the normal p53 allele. Surprisingly, in our study there were no K-ras mutations in p53 heterozygous lymphomas despite the fact that mutations in codon 12 of K-ras are common in MNU induced lymphomas. This may be explained by the observation by Kemp et al. (1993) showing that skin papillomas derived from p53 heterozygotes had mutant H-ras genes but did not exhibit a growth pro®le dierent than wild type controls, leading to the conclusion that activated ras and p53 are not cooperative. Interestingly, in this skin tumor/ initiation model, p53 heterozygous mice had an increased incidence of carcinomas, but papilloma incidence was similar to wild type, indicating that the p53 heterozygous state is involved in cancer promotion but not initiation (Kemp et al., 1993) .
A well-characterized event in p53 carcinogenesis is the loss of the remaining wild type allele via deletion, chromosome loss, and sometimes nondisjunction or reduplication (Levine et al., 1991; Nigro et al., 1989) . We found no gross chromosomal rearrangements or deletions in 15 of 17 p53 heterozygous lymphomas, and only one point mutation in a p53`hot spot' in one of nine mice. This is in contrast to Ohgaki et al. (2000) who found a loss of the wild type allele in 8 of 8 thymic lymphomas in p53 heterozygote mice after MNU, and others who have shown loss of heterozygosity at a lower rate in various other tumors (Kemp et al., 1993; Harvey et al., 1993) . The dierence between our study and that of Ohgaki et al. (2000) may result from the dose and route of MNU administration. In the Ohgaki study, mice given multiple low doses of MNU intragastrically developed lymphomas with a mean latency of 209 days and a loss of the wild type allele. In this study, one higher dose of MNU given i.p. resulted in a mean latency which was a substantially shorter 106 days (with a range of only 70 ± 190 days) and infrequent loss of the wild type allele. This dierence suggests that high dose MNU results in early lymphomas likely due to unrepaired O 6 mG lesions, whereas low dose chronic exposure, associated with a longer latency, leads to lymphomas due to loss of the remaining p53. It is also possible that in our model, mutations were present, but located outside of exons 5 ± 8. On the other hand, p53 mutations have proven to be infrequent in other models such as human medullablastomas (Saylors et al., 1991) , human hepatocellular carcinomas (Hosono et al., 1991) and in murine lung and liver tumors (Goodrow et al., 1992) after carcinogen exposure. Additionally, we found in a small number of tumors that there is no loss of p53 function based on the normal level of p21. Taken together, these results indicate that inactivation of the remaining p53 did not play a role in this model of MNU induced lymphomagenesis in p53 heterozygous mice. In the absence of p53 inactivation or oncogene activation, the explanation for increased lymphomas in our mice after MNU may be the gene dose of p53. Given the fact that wild type p53 acts as a`checkpoint' control protein that stops cell cycle before S phase when DNA damage is present it is not surprising that mice with only half the normal level of p53 are sensitive to methylating agent damage. In the scenario with abnormal p53, the cell may survive, replicating past O 6 mG, passing carcinogenic mutations to daughter cells and ultimately giving rise to T-cell lymphomas. Since p53 heterozygote cells are genetically unstable subsequent alterations may contribute to malignant transformation. This would explain why overexpression of the MGMT transgene, and AGT-mediated rapid removal of O 6 mG adducts, protects against MNU potentiation of lymphomagenesis in mice lacking one allele of p53: the mutagenic cascade is not triggered.
Other models have demonstrated that MNU acts cooperatively with mice genetically predisposed to tumors and that overexpression of MGMT can provide protection. Mice overexpressing LMO1 were highly susceptible to MNU, with a lymphoma incidence of 91% that was reduced to 15% in the presence of the hMGMT transgene (Allay et al., 1997) . In non-MGMT transgenics, K-ras mutations accounted for half of the early developing lymphomas in LMO1 mice. We have also shown that mice defective in the mismatch repair gene PMS-2 are also hypersensitive to MNU (Qin et al., 1999a,b) . In each instance, overexpression of hMGMT protects these mice from MNU hypersensitivity, again supporting the concept that O 6 mG is the oending lesion after MNU. These individual mouse models point to the complexity of murine lymphomagenesis. Remarkably, the mismatch repair, LMO1 and p53 pathways appear distinct but the de®ciency in each appears independently to lead to a ®nal common pathway of T-cell lymphomas with variable involvement of K-ras activation.
In summary, we have shown that MNU potentiates lymphoma induction in mice de®cient in one p53 allele. The increase in tumors results from unrepaired O 6 mG adducts since repair of these lesions by the DNA repair protein AGT overexpressed in the thymus prevents tumor formation. Of note, residual mutagenesis of MNU is not carcinogenic, even in the setting of partial p53 de®ciency. We suggest that AGT plays a key role in protecting the genome from carcinogenic O 6 mG DNA adducts which can themselves act cooperatively with the genetically predisposed state.
Materials and methods
Dosing and monitoring of mice p53 mice (C57BI/6 strain) were kindly provided by Larry Donehower. F1 progeny of MGMT6p53 were given 50 mg/ kg MNU i.p. at 6 weeks of age. MNU was made fresh in 5% acetic acid, diluted in PBS and used within 10 min. Mice were monitored for 1 year for the development of thymic lymphomas and sacri®ced upon exhibiting symptoms (labored breathing and weight loss). After sacri®ce, thymus, spleen, lung, liver and kidney sections were ®xed in 10% buered formalin, embedded in paran, sectioned and stained with hematoxylin and eosin. Sections were examined microscopically for the presence of lymphoma cells.
Detection of k-ras mutations
Activating point mutations in codon 12 of K-ras were identi®ed as previously described (Allay et al., 1997) . Brie¯y, a ®rst ampli®cation using the 5' primer (5' TAT AAA CTT GTG GTT GGA CCT 3') introduced a single mismatch that created a BstNI restriction site (CCTGG) in wild type codon 12. Wild type and mutant K-ras alleles were dierentiated by digestion with BstNI. A second ampli®cation using the 5' primer (5' ACC TTG TGG TGG TTG GAG GTG 3') introduced a mismatch creating an HphI recognition site (GGTGA) in mutant codon 12. The G to A mutation was con®rmed by digestion with HphI.
Flow cytometry
Single cell suspensions of thymic lymphomas were prepared by mincing fresh tissue and ®ltering through a 100 mm nylon mesh. 2610 6 cells were incubated with rat antimouse monoclonal antibodies PE-conjugated CD4 and FITC conjugated CD8 or PE-conjugated Thy 1.2 and FITC-conjugated TCR a/b (BD PharMingen). Stained cells were analysed on a Becton Dickinson FACScan using Cell Quest software.
PCR detection of wild type and mutant p53
Genomic DNA was extracted from thymic lymphomas by digestion with Proteinase K (10 mg/ml) and SDS (0.5%). DNA was diluted 1 : 10 and 5 ml was ampli®ed under the following conditions: denaturation 1 min at 948C, annealing 1 min at 608C and extension 1 min at 728C. The products were run on a 2% agarose gel. The p53 wild type allele was detected using the primers: (5'-GTG TTT CAT TAG TTC CCC ACC TTG AC 3'; 5'ATG GGA GGC TGC CAG TCC TAA CCC-3') and the mutant allele was detected using the primers: (5'-GTG GGA GGG ACA AAA GTT CGA GGC C-3'; 5'-TTT ACG GAG CCC TGG CGC TCG ATG T-3').
Sequencing
Exons 5 ± 8 of p53 were PCR ampli®ed from lymphoma DNA and agarose gel puri®ed (Agarose Gel Extraction Kit, Qiagen). DNA from each exon was subjected to automated sequencing in both the sense and anti-sense direction and compared to published sequences. PCR and sequencing primers were as published (Goodrow et al., 1992) .
p21 expression
Mice exhibiting labored breathing were irradiated with 500 cGy 60 Co. Four hours later, mice were sacri®ced and thymic lymphoma tissue was obtained. Fifty grams protein from lymphomas was electrophoresed and transferred to PVDF membrane followed by incubation with 5 g/ml anti mouse p21 (BD PharMingen). Anti mouse-HRP conjugated secondary antibody and chemiluminescent substrate (ECL, Amersham) was used for detection.
